Vernalis to get €0.75m milestone payment from Servier

The agreement allows Vernalis to receive fees and research milestones and a share in the downstream success of the product in the form of further milestones and royalties on sales.

Under the contract, the companies have used Vernalis’ proprietary fragment and structure-based drug discovery platform for the discovery of the oncology drugs.

Servier Research and Development president Emmanuel Canet said that they are satisfied with this collaboration reaching an important milestone on a truly oncology target.

“This is a step further in our aim to finalise the discovery of compounds with potential use in therapeutic indications with high unmet medical need,” Canet said.